Paper Details

  1. Home
  2. Paper Details

Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.

Author: BaldelliF, BifulcoG, CiprianiS, FiorucciS, MencarelliA, ZampellaA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

6-ethyl-chendeoxycholic acid (6E-CDCA) is a drug being developed to treat cholestatic liver diseases and liver-related metabolic disorders. In a clinical trial, 6E-CDCA met the primary endpoint of reducing alkaline phosphatase levels, but also exacerbated pruritus, a common symptom of primary biliary cirrhosis. 6E-CDCA also slightly reduced HDL levels and increased LDL levels.
Paper Details　
Original Abstract of the Article :
6-ethyl-chedeoxycholic acid (6E-CDCA) is a farnesoid X receptor (FXR) ligand endowed with agonistic activity under development for treatment of cholestatic liver diseases including primary biliary cirrhosis (PBC) and liver-related metabolic disorders including non-alcoholic fatty liver disease (NAFL...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2174/138955711796355258

データ提供：米国国立医学図書館（NLM）

Farnesoid X Receptor Agonist for Liver and Metabolic Disorders

This research explores the therapeutic potential of farnesoid X receptor (FXR) agonists, specifically 6-ethyl-chenodeoxycholic acid (6E-CDCA), for treating liver and metabolic disorders. The study examines the effects of 6E-CDCA in preclinical models and human clinical trials, focusing on its efficacy in cholestatic liver diseases and metabolic disorders. The findings provide valuable insights into the role of FXR agonists in managing these complex conditions.

Navigating the Desert of Liver Disease

The study's findings suggest that 6E-CDCA, an FXR agonist, holds promise for treating cholestatic liver diseases and metabolic disorders. The drug demonstrated efficacy in preclinical models, and while human clinical trials showed some positive effects, they also revealed potential side effects related to pruritus and lipid metabolism. These findings highlight the need for further research to optimize the therapeutic use of FXR agonists, balancing their benefits with potential risks.

FXR Agonists: A New Oasis in Liver Health?

The search for effective treatments for liver and metabolic disorders is akin to a journey through a vast and challenging desert. This research explores the potential of FXR agonists as a new oasis in this landscape, offering hope for improving the lives of patients. While promising, the study emphasizes the importance of careful evaluation and optimization of these agents to maximize their therapeutic benefits while mitigating potential adverse effects.

Dr. Camel's Conclusion

FXR agonists, like 6E-CDCA, may hold promise for treating liver and metabolic disorders, offering a refreshing oasis in the desert of disease. The study highlights the need for ongoing research to further refine these agents, ensuring their safe and effective use for patients.
Date :
  1. Date Completed 2011-12-14
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

21707532

DOI: Digital Object Identifier

10.2174/138955711796355258

Related Literature

Article Analysis
・Side Effects of obeticholic acid
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.